Median effective dose of oliceridine inhibiting the intubation response when combined with propofol during rigid bronchoscopy in elderly patients with lung cancer

Clinical Observation of Oliceridine Fumarate Injection in Comfortable Diagnosis and Treatment of Outpatient Endoscopic Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500109653

Enrollment

Unknown

Registered

2025-09-23

Start date

2024-12-12

Completion date

Unknown

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Test group:During the induction of general anesthesia, the first patient was intravenously injected with oxalidine at an initial dose of 40 ug/kg, followed by intravenous injection of propofol 1 mg/kg

Eligibility

Sex/Gender

All

Age

58 Years to 78 Years

Inclusion criteria

Inclusion criteria: 1. Age > 58 years old, both sexes, body mass index 20-28 kg/m2, ASA ?-?; 2. Operation time < 3h; 3. Patients voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with previous history of sedative, analgesic drugs and vasoactive drugs; 2. Severe heart and lung diseases, liver and kidney dysfunction before operation; 3. Disturbance of water, electrolyte and acid-base balance; 4. Acute hemorrhage in the larynx and trachea; 5. acute respiratory infections; 6. Rigid bronchoscope can not be inserted because of limited head retrusion.

Design outcomes

Primary

Measure	Time frame
ED50, ED95 and 95% confidence interval (CI) of oxalidine inhibiting response to rigid bronchoscopy intubation in elderly patients with lung cancer;	—

Countries

China

Contacts

Public ContactHao Zhen

Xianyang Central Hospital

YeJing0603@163.com+86 182 9298 0982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026